+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Endometrial biopsies during treatment with subcutaneous pulsatile gonadotropin-releasing hormone and luteal-phase human chorionic gonadotropin



Endometrial biopsies during treatment with subcutaneous pulsatile gonadotropin-releasing hormone and luteal-phase human chorionic gonadotropin



International Journal of Fertility 33(5): 329-333



A high incidence of luteal phase defect (LPD) has been reported using subcutaneous pulsatile gonadotropin-releasing hormone for induction of ovulation. We reviewed all patients treated with the combination of subcutaneous pulsatile gonadotropin-releasing hormone during the follicular phase and human chorionic gonadotropin during the luteal phase (GnRH-hCG) who underwent endometrial biopsy during a treatment cycle. All of these patients had biopsy-proven LPD which persisted despite traditional therapy with progesterone vaginal suppositories and/or clomiphene citrate. The mean number of biopsies out of phase per patient prior to GnRH-hCG treatment was 2.8 +/- 0.2 (+/- SEM). When treated with GnRH-hCG, 15/16 patients (94%) showed a normal endometrial biopsy. The probability of this result occurring by chance alone allowing for a 50% treatment independent correction rate is less than .001. These results show that the combination of subcutaneous pulsatile gonadotropin-releasing hormone and luteal-phase human chorionic gonadotropin can result in normal endometrial maturation in a high percentage of cycles when administered as described. It appears to be an effective alternative to traditional treatment modalities for luteal phase defect should one be needed.

(PDF emailed within 1 workday: $29.90)

Accession: 040016067

Download citation: RISBibTeXText

PMID: 2904419



Related references

Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone: the role of supplemental human chorionic gonadotropin in the luteal phase. Fertility and Sterility 41(4): 546-550, 1984

Ovulation with sub cutaneous pulsatile gonadotropin releasing hormone the role of supplemental human chorionic gonadotropin in the luteal phase. Fertility & Sterility 41(4): 546-550, 1984

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility 79(5): 1123-1128, 2003

Differential response of the luteal phase and fertility in cattle following ovulation of the first-wave follicle with human chorionic gonadotropin or an agonist of gonadotropin-releasing hormone. Journal of Animal Science 74(5): 1074-1083, 1996

Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility 79(5): 1123-1128, 2003

Variations in L-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with a gonadotropin-releasing hormone agonist. Fertility and Sterility 90(3): 876-878, 2007

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertility and Sterility 93(3): 847-854, 2010

Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach. Fertility and Sterility 94(7): 2820-2823, 2011

Specific binding sites for gonadotropin releasing hormone lh chorionic gonadotropin low density lipoprotein prolactin and fsh in homogenates of human corpus luteum ii. concentrations throughout the luteal phase of the menstrual cycle and early pregnancy. Journal of Endocrinology 113(2): 317-328, 1987

Reproductive responses of dairy cows with ovarian cysts to simultaneous human chorionic gonadotropin or gonadotropin-releasing hormone and cloprostenol compared to gonadotropin-releasing hormone alone treatment. Veterinary World 8(5): 640-644, 2016

Role of gonadotropin-releasing hormone agonists, human chorionic gonadotropin (hCG), progesterone, and estrogen in luteal phase support after hCG triggering, and when in pregnancy hormonal support can be stopped. Fertility and Sterility 109(5): 749-755, 2018

Pulsatile gonadotropin releasing factor treatment in azoospermic patients who previously failed human menopausal gonadotropin human chorionic gonadotropin treatment. Journal of Endocrinological Investigation 8(SUPPL 3): 173, 1985

Effect of human chorionic gonadotropin administration on pituitary and luteal response to gonadotropin-releasing hormone. Hormone Research 32(5-6): 203-207, 1989

The treatment of luteal phase defects with pulsatile infusion of gonadotropin-releasing hormone. Fertility and Sterility 48(6): 933-936, 1987

Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin. Endocrinology 121(2): 612-618, 1987